nvTv Therapeutics' 15min chart indicates bearish momentum with MACD and KDJ death crosses.
ByAinvest
Friday, Dec 19, 2025 9:32 am ET1min read
VTVT--
Based on the 15-minute chart of nvTv Therapeutics, the MACD Death Cross and KDJ Death Cross indicators have been triggered, accompanied by a Bearish Marubozu pattern on December 18, 2025 at 16:00. This suggests that the stock price has the potential to continue declining, with a shift in momentum towards the downside and a higher likelihood of further decreases. Sellers are currently in control of the market, and the bearish momentum is expected to persist.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet